TherapeuticsMD, Inc. (NASDAQ:TXMD) has a beta value of 2.09 and has seen 1,723,117 shares traded in the last trading session. The company, currently valued at $364.87 Million, closed the last trade at $1.34 per share which meant it lost -$0.07 on the day or -4.96% during that session. The TXMD stock price is -222.39% off its 52-week high price of $4.32 and 36.57% above the 52-week low of $0.85. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.97 Million shares traded. The 3-month trading volume is 4.31 Million shares.
The consensus among analysts is that TherapeuticsMD, Inc. (TXMD) is an Overweight stock at the moment, with a recommendation rating of 2.2. 1 analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 9 have rated it as a Hold, with 7 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.14.
TherapeuticsMD, Inc. (NASDAQ:TXMD) trade information
Despite being -4.96% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Sep 15 when the TXMD stock price touched $1.42 or saw a rise of 5.63%. Year-to-date, TherapeuticsMD, Inc. shares have moved -44.63%, while the 5-day performance has seen it change 0.75%. Over the past 30 days, the shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) have changed -19.76%. Short interest in the company has seen 88.66 Million shares shorted with days to cover at 20.57.
Wall Street analysts have a consensus price target for the stock at $6.9, which means that the shares’ value could jump 414.93% from current levels. The projected low price target is $1.2 while the price target rests at a high of $13. In that case, then, we find that the current price level is +870.15% off the targeted high while a plunge would see the stock lose -10.45% from current levels.
TherapeuticsMD, Inc. (TXMD) estimates and forecasts
Figures show that TherapeuticsMD, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +5.51% over the past 6 months, with this year growth rate of -11.11%, compared to 16.1% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are -7.7% and 47.4% for the next quarter. Revenue growth from the last financial year stood is estimated to be +20%.
7 analysts offering their estimates for the company have set an average revenue estimate of $15.07 Million for the current quarter. 7 have an estimated revenue figure of $21.4 Million for the next quarter concluding in December 01, 2020. Year-ago sales stood $23.72 Million and $15.9 Million respectively for this quarter and the next, and analysts expect sales will grow by -36.5% for the current quarter and 34.6% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -14.6% over the past 5 years. Earnings growth for 2020 is a modest -21.3% while over the next 5 years, the company’s earnings are expected to increase by 21.8%.
TherapeuticsMD, Inc. (NASDAQ:TXMD)’s Major holders
Insiders own 12.67% of the company shares, while shares held by institutions stand at 71.24% with a share float percentage of 81.57%. Investors are also buoyed by the number of investors in a company, with TherapeuticsMD, Inc. having a total of 216 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 21.26 Million shares worth more than $26.58 Million. As of June 29, 2020, Blackrock Inc. held 7.81% of shares outstanding.
The other major institutional holder is Price (T.Rowe) Associates Inc, with the holding of over 19.17 Million shares as of June 29, 2020. The firm’s total holdings are worth over $23.96 Million and represent 7.04% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Price (T.Rowe) Small Cap Stock Fund and Fidelity Series Large Cap Stock Fund. As of June 29, 2020, the former fund manager holds about 3.36% shares in the company for having 9153312 shares of worth $11.44 Million while later fund manager owns 8.19 Million shares of worth $10.23 Million as of June 29, 2020, which makes it owner of about 3.01% of company’s outstanding stock.